Biosimilars, also known as follow-on biologics, continued to capture greater market share and foment stronger competition with reference or brand name drugs in 2021. Increasing the number of biosimilars in the market and amplifying uptake by payers, family medical practices and pharmacies could be a gamechanger for patients and a healthcare system trying to reduce the cost of life-changing medicines.
Biotech, Medtech, and pharma companies of all shapes, sizes, and focus areas are struggling to fill vacancies during a growth boom created by the pandemic and advancements in biomanufacturing, cell and gene therapy, and other bleeding-edge sectors. This ongoing boom has created an uber-competitive talent acquisition and retention environment that’s pushing hiring managers, talent leaders, and c-suite executives to evolve and adopt new talent hiring and retention strategies that give them a competitive hiring edge.
We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.
The ongoing pandemic response by the biopharma industry has been historic. Biotech companies and contract development and manufacturing organizations, along with the entire supply chain, have worked together to develop several SARS-CoV-2 vaccines, achieved Emergency Use Authorization(EUA) from the FDA, and began delivering desperately needed protection into people’s arms in less than a calendar year.
